113 related articles for article (PubMed ID: 30138519)
21. Effects of pentoxifylline and alpha lipoic acid on methotrexate-induced damage in liver and kidney of rats.
Armagan I; Bayram D; Candan IA; Yigit A; Celik E; Armagan HH; Uğuz AC
Environ Toxicol Pharmacol; 2015 May; 39(3):1122-31. PubMed ID: 25912852
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of nephrotoxicity and ototoxicity following amikacin administration once daily or every 48 hours in neonates.
Endo A; Hanawa K; Nemoto A; Ishikawa T; Kazama S; Kagami Y; Maebayashi Y; Katsumata N; Naito A; Kobayashi Y; Kawano Y; Hanawa T
Medicine (Baltimore); 2022 Oct; 101(43):e31425. PubMed ID: 36316882
[TBL] [Abstract][Full Text] [Related]
23. Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system.
Ghazi IM; Grupper M; Nicolau DP
Ann Clin Microbiol Antimicrob; 2017 Jan; 16(1):2. PubMed ID: 28095918
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous tissue release of amikacin from a fibrin glue/polyurethane graft.
Nishimoto K; Yamamura K; Fukase F; Kobayashi M; Nishikimi N; Komori K
J Infect Chemother; 2004 Apr; 10(2):101-4. PubMed ID: 15160303
[TBL] [Abstract][Full Text] [Related]
25. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen.
Conil JM; Georges B; Breden A; Segonds C; Lavit M; Seguin T; Coley N; Samii K; Chabanon G; Houin G; Saivin S
Int J Antimicrob Agents; 2006 Sep; 28(3):226-30. PubMed ID: 16908121
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and renal toxicity of three once-a-day doses of amikacin in cows.
Sumano H; Gutierrez L; Velazquez C; Hayashida S
Acta Vet Hung; 2005; 53(2):231-40. PubMed ID: 15959981
[TBL] [Abstract][Full Text] [Related]
27. Self-protection against aminoglycoside ototoxicity in guinea pigs.
Oliveira JA; Canedo DM; Rossato M; Andrade MH
Otolaryngol Head Neck Surg; 2004 Sep; 131(3):271-9. PubMed ID: 15365547
[TBL] [Abstract][Full Text] [Related]
28. Protective effect of edaravone against tobramycin-induced ototoxicity.
Asplund MS; Lidian A; Linder B; Takumida M; Anniko M
Acta Otolaryngol; 2009 Jan; 129(1):8-13. PubMed ID: 18607936
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
[TBL] [Abstract][Full Text] [Related]
30. Pentoxifylline prevents the meglumine antimonate-induced renal toxicity in rats, but not that induced by the inorganic antimony pentachloride.
de Moura FJ; Leal PP; de Souza Furtado R; Muniz-Junqueira MI; Veiga JP
Toxicology; 2008 Jan; 243(1-2):66-74. PubMed ID: 18022309
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment with pentoxifylline and N-acetylcysteine in liver ischemia reperfusion-induced renal injury.
Seifi B; Kadkhodaee M; Delavari F; Mikaeili S; Shams S; Ostad SN
Ren Fail; 2012; 34(5):610-5. PubMed ID: 22364443
[TBL] [Abstract][Full Text] [Related]
32. Hepatoprotective effects of early pentoxifylline administration on hepatic injury induced by concanavalin A in rat.
Mohamed DI; Elmelegy AA; El-Aziz LF; Abdel Kawy HS; AbdEl-Samad AA; El-Kharashi OA
Can J Physiol Pharmacol; 2014 Jun; 92(6):490-7. PubMed ID: 24886185
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacokinetic and clinical studies on amikacin in neonates].
Nishimura T; Tabuki K; Takashima T
Jpn J Antibiot; 1987 Jun; 40(6):1183-91. PubMed ID: 3669300
[TBL] [Abstract][Full Text] [Related]
34. Persistence of the otoprotective effect: how long does otoprotection against amikacin lasts?
Oliveira AA; Campos Mde S; Murashima Ade A; Rossato M; Hyppolito MA; Oliveira JA
Braz J Otorhinolaryngol; 2012 Dec; 78(6):47-50. PubMed ID: 23306567
[TBL] [Abstract][Full Text] [Related]
35. Memantine's action against aminoglycoside-induced ototoxicity.
Pavlidis P; Maurer J; Apostolidou E; Kekes G; Kouvelas D
Eur Arch Otorhinolaryngol; 2014 Jun; 271(6):1491-6. PubMed ID: 23917735
[TBL] [Abstract][Full Text] [Related]
36. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity.
Gálvez R; Luengo C; Cornejo R; Kosche J; Romero C; Tobar E; Illanes V; Llanos O; Castro J
Int J Antimicrob Agents; 2011 Aug; 38(2):146-51. PubMed ID: 21612894
[TBL] [Abstract][Full Text] [Related]
37. [Protective effect by piperacillin against renal impairment caused by amikacin].
Kusafuka H; Obayashi T; Iwayama N; Sezaki R; Izuhara Y; Yoshida H; Goto M; Maeda K
Nihon Jinzo Gakkai Shi; 1992 Feb; 34(2):153-62. PubMed ID: 1588766
[TBL] [Abstract][Full Text] [Related]
38. Ototoxicity associated with a once daily dose amikacin regimen in febrile neutropenic patients.
Kibbler CC; McWhinney PH; Warner P; Prentice HG
J Antimicrob Chemother; 1992 Apr; 29(4):463-4. PubMed ID: 1607336
[No Abstract] [Full Text] [Related]
39. Therapeutic and protective effects of autologous serum in amikacin-induced ototoxicity.
Arslan IB; Aslan GG; Mercan GC; Vatansever S; Cukurova I; Gokalp S; Aslan A
J Laryngol Otol; 2018 Jan; 132(1):33-40. PubMed ID: 29151378
[TBL] [Abstract][Full Text] [Related]
40. [Studies on the intravenous administration of amikacin to neonates].
Masumi R; Hirama Y; Narita A; Nakazawa S; Iwasaki A; Niino K; Sato H; Nakazawa S; Tazoe K; Chikaoka H
Jpn J Antibiot; 1987 Jun; 40(6):1146-56. PubMed ID: 3669297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
